- If you are wondering whether Encompass Health stock is pricing in too much optimism or still offering value, the current setup makes it an interesting case to examine more closely.
- The share price recently closed at US$101.33, with the stock up 2.7% over the past week but down 4.3% over the past month, 4.7% year to date, and 16.8% over the past year, while still showing gains of 54.0% over three years and 64.3% over five years.
- Recent coverage has focused on Encompass Health's position in the US healthcare sector and ongoing discussion around rehabilitation services. This helps frame how investors think about its long term role in patient care and potential capital allocation priorities. These themes often feed into how the market weighs both upside potential and the risks embedded in the current share price.
- Against that backdrop, Encompass Health currently scores a valuation check score of 6 out of 6. The next step is to unpack how different valuation approaches view the stock and then consider a broader way to interpret those numbers by the end of this article.
Find out why Encompass Health's -16.8% return over the last year is lagging behind its peers.
Approach 1: Encompass Health Discounted Cash Flow (DCF) Analysis
A Discounted Cash Flow, or DCF, model estimates what Encompass Health stock could be worth by projecting future cash flows and discounting them back to today, so you can compare that value with the current share price.
For Encompass Health, the model uses a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The latest twelve month Free Cash Flow stands at about $457.3 million. Analyst inputs extend to $576.0 million of projected Free Cash Flow in 2028, and further out to 2035 Simply Wall St extrapolates estimates that range from about $409.7 million in 2026 up to $835.2 million in 2035, all in dollar terms.
After discounting these projected cash flows back to today, the model arrives at an estimated intrinsic value of about $165.36 per share for Encompass Health. Compared with the recent share price of $101.33, this suggests the stock is trading at roughly a 38.7% discount to that DCF estimate.
Result: UNDERVALUED according to this DCF model
Our Discounted Cash Flow (DCF) analysis suggests Encompass Health is undervalued by 38.7%. Track this in your watchlist or portfolio, or discover 44 more high quality undervalued stocks.
Approach 2: Encompass Health Price vs Earnings
For profitable companies like Encompass Health, the P/E ratio is a useful way to think about what you are paying for each dollar of current earnings. It ties the share price directly to the company’s profitability, which tends to matter most once a business is already earning consistent profits.
In general, higher expected earnings growth and lower perceived risk can support a higher P/E ratio, while slower expected growth or higher risk usually point to a lower “normal” or “fair” P/E range. That context helps you judge whether a given multiple looks high, low, or roughly in line with what you might expect.
Encompass Health currently trades on a P/E of 16.97x. This is slightly below the peer average of 17.14x and below the broader Healthcare industry average of 25.07x. Simply Wall St also calculates a proprietary “Fair Ratio” for Encompass Health of 21.93x, which reflects factors such as earnings growth characteristics, profit margins, industry, market cap and company specific risks. Because this Fair Ratio is tailored to the company, it can give a more tailored signal than a simple comparison with peers or sector averages.
Compared with the current P/E of 16.97x, the Fair Ratio of 21.93x suggests Encompass Health stock is trading below that company specific reference point.
Result: UNDERVALUED
P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.
Upgrade Your Decision Making: Choose your Encompass Health Narrative
Earlier it was mentioned that there is an even better way to understand what all these valuation numbers mean. On Simply Wall St that starts with Narratives, which are clear, user defined stories about Encompass Health that link your view of its role in rehabilitation, your assumptions for future revenue, earnings and margins, and your estimate of fair value into one joined up forecast that can be compared with the current share price to help you decide whether the stock looks expensive or cheap right now.
On the Simply Wall St Community page, Narratives are presented in an accessible format so you can see how different investors connect Encompass Health's clinical model, capital spending, reimbursement exposure and technology investments to their own set of forecasts. Importantly, these Narratives refresh when new information such as earnings, fresh price targets or company news is added so that fair values and key drivers do not become stale.
For example, one Narrative for Encompass Health might lean closer to the lower analyst fair value reference of about US$99.17 with more conservative assumptions, while another could sit nearer the higher analyst fair value reference of about US$140.50. By comparing that range with the current market price you can decide which story lines up best with your expectations before making any buy or sell decision of your own.
For Encompass Health, however, we will make it really easy for you with previews of two leading Encompass Health Narratives:
Fair value used in this bullish narrative: US$140.50 per share.
At the recent price of US$101.33, this narrative treats the stock as about 27.9% below its fair value estimate.
Revenue growth assumption used in this view: 8.18% a year.
- Focuses on demographic tailwinds and limited inpatient rehab capacity as key supports for demand across Encompass Health's hospital footprint.
- Highlights analyst expectations for rising margins, higher earnings and share count reduction, all discounted using a 7.11% rate.
- Flags risks around labor shortages, heavy capital spending, reimbursement dependence and potential disruption from alternative rehab models and new technology.
Fair value used in this more cautious narrative: US$99.17 per share.
At the recent price of US$101.33, this narrative treats the stock as about 2.2% above its fair value estimate.
Revenue growth assumption used in this view: 7.89% a year.
- Centers on Encompass Health's role in long term recovery outcomes, where readmission rates and sustained patient progress are key to financial performance.
- Argues that relationship focused, outcome based care models can be an advantage but require careful coordination across clinical teams and treatment modalities.
- Suggests that operational quality, treatment philosophy and resilience focused programs are increasingly important drivers for how investors weigh the stock over time.
Seen together, these two Narratives bracket a fair value range of roughly US$99 to US$141. This gives you a concrete framework for testing your own assumptions about Encompass Health's growth, margins and execution before making any decision.
Do you think there's more to the story for Encompass Health? Head over to our Community to see what others are saying!
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com